Centrum Alergologii Teresa Hofman Sp. z o.o.

Poznan 10 trials

10 Registered trials

0 Currently recruiting

Organisation

Centrum Alergologii Teresa Hofman Sp. z o.o.

Location

Poznan, Poland

Identifier

ORG-100046139

Address

Ul. Wojciecha Boguslawskiego 16a, 60-214, Poland

Departments

Allergology
Centrum Alergologii sp. z o.o.
N/A
NA

Clinical trials at this site (10)

Search interface

Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending

2023-507427-28-00 seasonal allergic rhinitis and/or rhinoconjunctivitis 5
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Ended

2023-508817-18-00 Perennial Allergic Rhinitis (PAR) 5 2024-10-08
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended

2023-504942-75-01 Moderate to Severe Allergic Rhinitis/Rhinoconjunctiviti 5 2024-08-22
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended

2024-514764-72-00 Chronic Urticaria 5 2023-09-27
A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o… Ended

2023-509833-38-00 Birch Pollen-induced Allergic Rhinoconjunctivitis 5 2023-09-20
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Atopic Dermatitis 5 2023-05-23
A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153… Ended

2023-510172-31-00 Chronic obstructive pulmonary disease (COPD) 5 2022-04-22
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-507093-40-00 Chronic Obstructive Pulmonary Disease (COPD) 4 2022-01-27